Neurology · Bipolar DisorderTrial Updateclinicalmid-term

Bristol-Myers Squibb Evaluates KarXT for Bipolar-I Disorder Manic Episodes

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/29/2026, 12:31:00 AM

Assessment confidence: 80% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing clinical trial for KarXT could significantly impact Bristol-Myers Squibb's position in the psychiatric disorder market. Positive results may enhance their portfolio and competitive standing against existing therapies for Bipolar-I Disorder. Regulatory context from FDA (FDA AP — OPDIVO QVANTIG (SUPPL)) supports the near-term read. Assessment grounded in 28 ranked evidence items (20 high-relevance).

Strategic Assessment

Success in this trial could enhance Bristol-Myers Squibb's portfolio in psychiatric disorders, influencing future development strategies. The strongest clinical anchor is Trial of an Online Spanish Pivotal Response Treatment Training in Autism Spectrum Disorder (ClinicalTrials.gov), sponsor/company relevance (bristol myers squibb). In Neurology · Bipolar Disorder, 8 regulatory and 8 competitive items passed relevance filtering for Bristol Myers Squibb.

Competitive Pressure

The most relevant competitive pressure comes from Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial (Bristol Myers Squibb) — entity match (bristol myers squibb).

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — OPDIVO QVANTIG (SUPPL) (FDA). Sponsor/company relevance (Bristol Myers Squibb); Regulatory pathway relevance (bla). The trial's outcomes will be critical for regulatory approval processes, influencing labeling and compliance for KarXT in the treatment of Bipolar-I Disorder.

Key Risks

Elevated medium regulatory exposure for Bristol Myers Squibb could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Success in this trial could lead to increased market share for Bristol-Myers Squibb, potentially translating into substantial revenue growth in the psychiatric treatment segment.
Bristol Myers Squibb document relevant to the signal.
Upside for Bristol Myers Squibb may improve if Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder (ClinicalTrials.gov) delivers favorable follow-through.
Success in this trial could enhance Bristol-Myers Squibb's portfolio in psychiatric disorders, influencing future development strategies.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any announcements regarding efficacy and safety outcomes.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — OPDIVO QVANTIG (SUPPL)
FDAhigh relevance
Sponsor/company relevance (Bristol Myers Squibb); Regulatory pathway relevance (bla)
FDA document
View source
FDA AP — YERVOY (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb); Regulatory pathway relevance (bla)
FDA document
View source
FDA AP — YERVOY (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb); Regulatory pathway relevance (bla)
FDA document
View source
FDA AP — YERVOY (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb); Regulatory pathway relevance (bla)
FDA document
View source
FDA AP — OPDUALAG (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb); Regulatory pathway relevance (bla)
FDA document
View source
FDA AP — REVLIMID (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OPDIVO (SUPPL)
FDAhigh relevance
Entity match (bristol myers squibb); Regulatory pathway relevance (bla)
FDA document
View source
FDA AP — THALOMID (SUPPL)
FDAhigh relevance
Sponsor/company relevance (Bristol Myers Squibb); Regulatory pathway relevance (nda)
FDA document
View source

Trial of an Online Spanish Pivotal Response Treatment Training in Autism Spectrum Disorder
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Tirzepatide in the Treatment of Cannabis Use Disorder: A Proof-of-Concept Study
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Efforts to Increase Representation in Prostate Cancer Clinical Trials at Lyndon B.
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source

Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
Bristol Myers Squibbhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schiz
Bristol Myers Squibbhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
Bristol Myers Squibbhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)
Bristol Myers Squibbhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
Bristol Myers Squibbhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Bristol Myers Squibbhigh relevance
Entity match (bristol myers squibb)
FDA document
View source
Phase 3 Study of Radiprodil in GRIN-related Neurodevelopmental Disorder Initiated
Humanexa Signalsmedium relevance
Sponsor/company relevance (Bristol Myers Squibb)
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalsmedium relevance
Sponsor/company relevance (Bristol Myers Squibb)

Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Bristol Myers Squibb
Bipolar-I Disorder market

Commercial impact

medium

Success in this trial could lead to increased market share for Bristol-Myers Squibb, potentially translating into substantial revenue growth in the psychiatric treatment segment.

Regulatory impact

medium

The trial's outcomes will be critical for regulatory approval processes, influencing labeling and compliance for KarXT in the treatment of Bipolar-I Disorder.

What to watch

Monitor trial results and any announcements regarding efficacy and safety outcomes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.